| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article; Review
- Language: English
- [Br J Haematol] 2024 May; Vol. 204 (5), pp. 1605-1616. <i>Date of Electronic Publication: </i>2024 Apr 08.
- MeSH Terms: Thrombocythemia, Essential* / drug therapy ; Thrombocythemia, Essential* / genetics ; Humans ; Janus Kinase 2 / genetics ; Janus Kinase 2 / antagonists & inhibitors ; Platelet Aggregation Inhibitors / therapeutic use ; Platelet Aggregation Inhibitors / adverse effects ; Mutation ; Receptors, Thrombopoietin / agonists ; Receptors, Thrombopoietin / genetics ; Calreticulin
- References: Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–1228. ; Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719. ; Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129(6):667–679. ; Zoi K, Cross NC. Genomics of myeloproliferative neoplasms. J Clin Oncol. 2017;35(9):947–954. ; Srour SA, Devesa SS, Morton LM, Check DP, Curtis RE, Linet MS, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001‐12. Br J Haematol. 2016;174(3):382–396. ; Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map. Blood Rev. 2020;42:100706. ; Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long‐term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–2513. ; Cervantes F, Alvarez‐Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol. 2002;118(3):786–790. ; Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5:e366. ; Alvarez‐Larran A, Cervantes F, Bellosillo B, Giralt M, Julia A, Hernandez‐Boluda JC, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21(6):1218–1223. ; Godfrey AL, Green A, Harrison CN. Essential thrombocythemia: challenges in clinical practice and future prospects. Blood. 2023;141(16):1943–1953. ; Campbell PJ, MacLean C, Beer PA, Buck G, Wheatley K, Kiladjian JJ, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012;120(7):1409–1411. ; Alvarez‐Larran A, Pereira A, Guglielmelli P, Hernandez‐Boluda JC, Arellano‐Rodrigo E, Ferrer‐Marin F, et al. Antiplatelet therapy versus observation in low‐risk essential thrombocythemia with a CALR mutation. Haematologica. 2016;101(8):926–931. ; Alvarez‐Larran A, Cervantes F, Pereira A, Arellano‐Rodrigo E, Perez‐Andreu V, Hernandez‐Boluda JC, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low‐risk essential thrombocythemia. Blood. 2010;116(8):1205–1210. ; Rottenstreich A, Kleinstern G, Krichevsky S, Varon D, Lavie D, Kalish Y. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. Eur J Intern Med. 2017;41:49–54. ; van Genderen PJ, van Vliet HH, Prins FJ, van de Moesdijk D, van Strik R, Zijlstra FJ, et al. Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Ann Hematol. 1997;75(5–6):215–220. ; Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an international prognostic score of thrombosis in World Health Organization‐essential thrombocythemia (IPSET‐thrombosis). Blood. 2012;120(26):5128–5133. ; Barbui T, Vannucchi AM, Buxhofer‐Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Practice‐relevant revision of IPSET‐thrombosis based on 1019 patients with WHO‐defined essential thrombocythemia. Blood Cancer J. 2015;5:e369. ; Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, et al. Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET‐thrombosis) in 585 mayo clinic patients. Am J Hematol. 2016;91(4):390–394. ; Alvarez‐Larran A, Cuevas B, Velez P, Noya S, Caballero‐Navarro G, Ferrer‐Marin F, et al. Application of IPSET‐thrombosis in 1366 patients prospectively followed from the Spanish registry of essential Thrombocythemia. HemaSphere. 2023;7(8):e936. ; Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189(2):291–302. ; Loscocco GG, Guglielmelli P, Gangat N, Rossi E, Mannarelli C, Betti S, et al. Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: a multicenter study involving 1607 patients. Am J Hematol. 2021;96(11):1472–1480. ; Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416–1430. ; Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva‐Kyuchukova L, Egyed M, et al. Ropeginterferon alfa‐2b versus standard therapy for polycythaemia vera (PROUD‐PV and CONTINUATION‐PV): a randomised, non‐inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196–e208. ; Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O'Sullivan J, et al. Ruxolitinib versus best available therapy for polycythemia Vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023;41(19):3534–3544. ; Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome‐negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057–1069. ; Guidelines N. Myeloproliferative neoplasms. 2023(Version 3.2023):Version 3.2023. ; Godfrey AL, Campbell PJ, MacLean C, Buck G, Cook J, Temple J, et al. Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high‐risk features. J Clin Oncol. 2018;36(34):3361–3369. ; Alvarez‐Larran A, Pereira A, Arellano‐Rodrigo E, Hernandez‐Boluda JC, Cervantes F, Besses C. Cytoreduction plus low‐dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high‐risk essential thrombocythaemia: an observational study. Br J Haematol. 2013;161(6):865–871. ; Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia‐negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–770. ; Landolfi R, Marchioli R. European collaboration on low‐dose aspirin in polycythemia Vera (ECLAP): a randomized trial. Semin Thromb Hemost. 1997;23(5):473–478. ; Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta‐analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–1860. ; Antithrombotic Trialists C. Collaborative meta‐analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. ; Patrono C, Andreotti F, Arnesen H, Badimon L, Baigent C, Collet JP, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011;32(23):2922–2932. ; De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93(3):372–380. ; Rocca B, Tosetto A, Betti S, Soldati D, Petrucci G, Rossi E, et al. A randomized double‐blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood. 2020;136(2):171–182. ; Cattaneo M. Aspirin in essential thrombocythemia. For whom? What formulation? What regimen? Haematologica. 2023;108(6):1487–1499. ; Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99:697–718. ; Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132–1136. ; Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, et al. Interferon alpha therapy in essential thrombocythemia and polycythemia vera‐a systematic review and meta‐analysis. Leukemia. 2021;35(6):1643–1660. ; Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, et al. Pegylated interferon alfa‐2a in patients with essential thrombocythaemia or polycythaemia vera: a post‐hoc, median 83 month follow‐up of an open‐label, phase 2 trial. Lancet Haematol. 2017;4(4):e165–e175. ; Mascarenhas J, Kosiorek HE, Prchal JT, Rambaldi A, Berenzon D, Yacoub A, et al. A randomized phase 3 trial of interferon‐alpha vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022;139(19):2931–2941. ; Knudsen TA, Skov V, Stevenson K, Werner L, Duke W, Laurore C, et al. Genomic profiling of a randomized trial of interferon‐alpha vs hydroxyurea in MPN reveals mutation‐specific responses. Blood Adv. 2022;6(7):2107–2119. ; Quintas‐Cardama A, Abdel‐Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha‐2a. Blood. 2013;122(6):893–901. ; Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. Hydroxyurea compared with anagrelide in high‐risk essential thrombocythemia. N Engl J Med. 2005;353(1):33–45. ; Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, et al. Anagrelide compared with hydroxyurea in WHO‐classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood. 2013;121(10):1720–1728. ; Birgegard G, Besses C, Griesshammer M, Gugliotta L, Harrison CN, Hamdani M, et al. Treatment of essential thrombocythemia in Europe: a prospective long‐term observational study of 3649 high‐risk patients in the evaluation of Anagrelide efficacy and long‐term safety study. Haematologica. 2018;103(1):51–60. ; Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 2007;21(2):277–280. ; Verstovsek S, Komatsu N, Gill H, Jin J, Lee SE, Hou HA, et al. SURPASS‐ET: phase III study of ropeginterferon alfa‐2b versus anagrelide as second‐line therapy in essential thrombocythemia. Future Oncol. 2022;18(27):2999–3009. ; Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, et al. Clinical and molecular response to interferon‐alpha therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015;126(24):2585–2591. ; Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, et al. Pegylated interferon alfa‐2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134(18):1498–1509. ; Alvarez‐Larran A, Martinez‐Aviles L, Hernandez‐Boluda JC, Ferrer‐Marin F, Antelo ML, Burgaleta C, et al. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol. 2014;93(12):2037–2043. ; Alvarez‐Larran A, Angona A, Andrade‐Campos M, Soledad Noya M, Teresa Gomez‐Casares M, Cuevas B, et al. Cytoreductive treatment in patients with CALR‐mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish registry of essential Thrombocythaemia. Br J Haematol. 2021;192(6):988–996. ; Alvarez‐Larran A, Sant'Antonio E, Harrison C, Kiladjian JJ, Griesshammer M, Mesa R, et al. Unmet clinical needs in the management of CALR‐mutated essential thrombocythaemia: a consensus‐based proposal from the European LeukemiaNet. Lancet Haematol. 2021;8(9):e658–e665. ; Hernandez‐Boluda JC, Pereira A, Cervantes F, Gomez M, Arellano‐Rodrigo E, Alvarez‐Larran A, et al. Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. Ann Hematol. 2013;92(6):771–775. ; Mela Osorio MJ, Ferrari L, Goette NP, Gutierrez MI, Glembotsky AC, Maldonado AC, et al. Long‐term follow‐up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status. Eur J Haematol. 2016;96(4):435–442. ; Ito T, Hashimoto Y, Tanaka Y, Nakaya A, Fujita S, Satake A, et al. Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naive essential thrombocythemia patients in a real‐world setting. Eur J Haematol. 2019;103(2):116–123. ; Desterro J, McLornan DP, Curto Garcia N, O'Sullivan J, Alimam S, Keohane C, et al. Essential thrombocythaemia treated with recombinant interferon: ‘real world’ United Kingdom referral centre experience. Br J Haematol. 2019;186(4):561–564. ; Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, et al. MPL mutations in myeloproliferative disorders: analysis of the PT‐1 cohort. Blood. 2008;112(1):141–149. ; Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood. 2008;112(3):844–847. ; Alvarez‐Larran A, Martinez D, Arenillas L, Rubio A, Arellano‐Rodrigo E, Hernandez Boluda JC, et al. Essential thrombocythaemia with mutation in MPL: clinicopathological correlation and comparison with JAK2V617F‐mutated and CALR‐mutated genotypes. J Clin Pathol. 2018;71(11):975–980. ; Pich A, Riera L, Francia di Celle P, Beggiato E, Benevolo G, Godio L. JAK2V617F, CALR, and MPL mutations and bone marrow histology in patients with essential Thrombocythaemia. Acta Haematol. 2018;140(4):234–239. ; Guglielmelli P, Gangat N, Coltro G, Lasho TL, Loscocco GG, Finke CM, et al. Mutations and thrombosis in essential thrombocythemia. Blood Cancer J. 2021;11(4):77. ; Yang E, Wang M, Wang Z, Li Y, Wang X, Ming J, et al. Comparison of the effects between MPL and JAK2V617F on thrombosis and peripheral blood cell counts in patients with essential thrombocythemia: a meta‐analysis. Ann Hematol. 2021;100(11):2699–2706. ; Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, et al. MPL gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan. Hematology. 2023;28(1):2229131. ; Alimam S, Villiers W, Dillon R, Simpson M, Runglall M, Smith A, et al. Patients with triple‐negative, JAK2V617F‐ and CALR‐mutated essential thrombocythemia share a unique gene expression signature. Blood Adv. 2021;5(4):1059–1068. ; Michail O, McCallion P, McGimpsey J, Hindley A, Greenfield G, McAllister R, et al. Mutational profiling in suspected triple‐negative essential thrombocythaemia using targeted next‐generation sequencing in a real‐world cohort. J Clin Pathol. 2021;74(12):808–811. ; Acha P, Xandri M, Fuster‐Tormo F, Palomo L, Xicoy B, Cabezon M, et al. Diagnostic and prognostic contribution of targeted NGS in patients with triple‐negative myeloproliferative neoplasms. Am J Hematol. 2019;94(10):E264–E267. ; Cabagnols X, Favale F, Pasquier F, Messaoudi K, Defour JP, Ianotto JC, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple‐negative essential thrombocythemia patients. Blood. 2016;127(3):333–342. ; Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, et al. Whole‐exome sequencing identifies novel MPL and JAK2 mutations in triple‐negative myeloproliferative neoplasms. Blood. 2016;127(3):325–332. ; Furuya C, Morishita S, Hashimoto Y, Inano T, Ochiai T, Shirane S, et al. Impact of non‐driver gene mutations on thrombo‐haemorrhagic events in ET patients. Br J Haematol. 2024;204(1):221–228. ; Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, et al. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. Leukemia. 2015;29(5):1209–1210. ; Bertozzi I, Peroni E, Coltro G, Bogoni G, Cosi E, Santarossa C, et al. Thrombotic risk correlates with mutational status in true essential thrombocythemia. Eur J Clin Invest. 2016;46(8):683–689. ; Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M, et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol. 2016;91(5):503–506. ; Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111–121. ; Bhattacharya R, Zekavat SM, Haessler J, Fornage M, Raffield L, Uddin MM, et al. Clonal hematopoiesis is associated with higher risk of stroke. Stroke. 2022;53(3):788–797. ; Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age‐related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–2498. ; Wang Z, Liu W, Wang D, Yang E, Li Y, Li Y, et al. TET2 mutation may Be more valuable in predicting thrombosis in ET patients compared to PV patients: a preliminary report. J Clin Med. 2022;11(22):6615. ; Segura‐Diaz A, Stuckey R, Florido Y, Gonzalez‐Martin JM, Lopez‐Rodriguez JF, Sanchez‐Sosa S, et al. Thrombotic risk detection in patients with polycythemia Vera: the predictive role of DNMT3A/TET2/ASXL1 mutations. Cancers (Basel). 2020;12(4):934. ; Pasquer H, Daltro de Oliveira R, Vasseur L, Soret‐Dulphy J, Maslah N, Zhao LP, et al. Distinct clinico‐molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification. Leukemia. 2024;38(2):326–339. ; Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017;130(17):1889–1897. ; Senin A, Fernandez‐Rodriguez C, Bellosillo B, Camacho L, Longaron R, Angona A, et al. Non‐driver mutations in patients with JAK2V617F‐mutated polycythemia vera or essential thrombocythemia with long‐term molecular follow‐up. Ann Hematol. 2018;97(3):443–451. ; Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018;8(1):2. ; Valera MC, Parant O, Vayssiere C, Arnal JF, Payrastre B. Essential thrombocythemia and pregnancy. Eur J Obstet Gynecol Reprod Biol. 2011;158(2):141–147. ; Robinson SE, Harrison CN. How we manage Philadelphia‐negative myeloproliferative neoplasms in pregnancy. Br J Haematol. 2020;189(4):625–634. ; Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, et al. Efficacy and safety of ruxolitinib in patients with newly‐diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG‐MPN study group. Ann Hematol. 2023;102(2):349–358. ; Jutzi JS, Kleppe M, Dias J, Staehle HF, Shank K, Teruya‐Feldstein J, et al. LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone. HemaSphere. 2018;2(3):e54. ; Harinder Gill FP, Ross DM, Cochrane T, Tate C, Lane SW, Larsen SR, et al. A phase 2 study of the LSD1 inhibitor Bomedemstat (IMG‐7289) for the treatment of essential thrombocythemia (ET). Blood. 2022;140:1784–1787. ; Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva‐Kyuchukova L, Egyed M, et al. Long‐term outcomes of polycythemia vera patients treated with ropeginterferon Alfa‐2b. Leukemia. 2022;36(5):1408–1411. ; Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373(10):920–928. ; Oppliger Leibundgut E, Haubitz M, Burington B, Ottmann OG, Spitzer G, Odenike O, et al. Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat. Haematologica. 2021;106(9):2397–2404. ; Geron sponsore trials. https://www.geron.com/research‐and‐development/clinical‐trials/. ; Edimara Reis RB, Celik H, Marty C, Lei A, Jobe F, Rupar M, et al. Discovery of INCA033989, a monoclonal antibody that selectively antagonizes mutant calreticulin oncogenic function in myeloproliferative neoplasms. Blood. 2022;140:14–15. ; Handlos Grauslund J, Holmstrom MO, Jorgensen NG, Klausen U, Weis‐Banke SE, El Fassi D, et al. Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR‐mutant chronic myeloproliferative neoplasms. Front Oncol. 2021;11:637420.
- Grant Information: ´PI21/00347´(FF-M);´PI21/00538´(JCH-B);´PI21/00231´(AA-L) Instituto de Salud Carlos III:
- Contributed Indexing: Keywords: essential thrombocythaemia; myeloproliferative neoplasms; new drugs
- Substance Nomenclature: EC 2.7.10.2 (Janus Kinase 2) ; EC 2.7.10.2 (JAK2 protein, human) ; 0 (Platelet Aggregation Inhibitors) ; 143641-95-6 (MPL protein, human) ; 0 (Receptors, Thrombopoietin) ; 0 (CALR protein, human) ; 0 (Calreticulin)
- Entry Date(s): Date Created: 20240408 Date Completed: 20240513 Latest Revision: 20240513
- Update Code: 20240514
|
